Arena Pharmaceuticals (ARNA) Tops Q2 Loss Views by 1c
Arena Pharmaceuticals (Nasdaq: ARNA) reports Q2 loss of $0.28, cents better than the analyst estimate of ($0.29). Revenue for the quarter was $2.46 million, which compares to the estimate of $2.97 million.
You May Also Be Interested In
- Market Wrap: Chinese Stock Pressure Hits U.S. Markets; Durable Orders Outpace in June; Merger Monday
- Dice Holdings (DHX) Tops Q2 EPS by 1c, Offers Guidance, Plans to Sell Slashdot Media
- Planet Fitness (PLNT) Sets IPO Price at $14-$16/Share
Create E-mail Alert Related CategoriesEarnings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!